Addex Therapeutics Ltd - American Depositary Shares (ADXN)
7.6600
+0.1100 (1.46%)
Addex Therapeutics Ltd is a biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders
The company leverages its expertise in allosteric modulation to identify and develop novel therapies aimed at a variety of conditions, including addiction, anxiety, and epilepsy. By utilizing its proprietary technology platform, Addex works to create safer and more effective therapeutic options that can enhance patient outcomes and address unmet medical needs in the complex field of brain health.
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the agreement, while advancing its own GABAB PAM program for chronic cough.
Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care.
